Kidney, Liver, Soft Tissue, Thyroid
Principal Investigator: Dr. Alice Lee
ADVL1121: A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib
(IND# 69896) in Children and Young Adults with Relapsed/Refractory Rhabdomyosarcoma, Wilms
Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma
This is a phase II, multi-center study of Sorafenib, an agent that acts as a control in tumor growth. The purpose of this study is to determine the response rate to as well as evaluate the toxicities of Sorafenib in children and young adults with relapsed (cancers that have come back after being treated before) Rhabdomyosaroma, Wilma Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma. Sorafenib will be given every 12 hours as tablets. The therapy will last up to 28 days and the doctor may ask you to visit after to complete follow-up tests. Participants can receive up to 24 cycles of therapy continuously. There will be about 80 patients participating in this study overall and about 6 will be treated at Columbia University Medical Center. The study treatment is considered experimental because it is not approved by the United States (US) Food and Drug Administration (FDA) for treating children and young adults with solid tumors. Please click here to view more information in ClinicalTrials.gov.
For more information and to inquire about eligibility for this study, please contact the Cancer Center office at 212-305-8615.